- Inicio
- Innovación y Tecnología
- Transferencia de Tecnología
- Ofertas de tecnología seleccionadas
Ofertas de tecnología seleccionadas
En esta sección le presentamos las últimas ofertas de tecnología incorporadas en la red EEN.
Si está interesado en un sector tecnológico determinado, pulsando el título correspondiente, obtendrá las ofertas relacionadas con dicho sector. (Pulse en un sector tecnológico determinado y encontrará todas las ofertas de dicho sector.)
Title
Serpin inhibitors for the treatment of prion and prion like diseases
Reference
TOIT20210421001
Last update
Thu, Apr, 29, 2021
Deadline
Fri, Apr, 29, 2022
Abstract
A research group based in Italy has developed a new class of small molecules acting as SERPINA3 inhibitors, which are able to reduce prion protein (PrPSc) accumulation in prion-infected cell lines, thereby representing a new therapeutic treatment against prion and prion-like diseases. They are looking for licence agreements and joint venture agreements with pharma companies and/or financial agreements with investors.
Description
To date, despite numerous active efforts, there are no drugs available for the cure of the neurodegenerative diseases collectively referred as prion and prion-like disorders. Symptomatic treatment is the only available option, including the administration to patients of anti-psychotics, such as quetiapine and clonazepam, to treat myoclonus and of selective serotonin re-uptake inhibitors (SSRIs) to treat depression.
Indeed, through this invention, the technology transfer office of a research center based in the North of Italy and internationally renowned, is presenting a new class of small molecules. These small molecules are acting as SERPINA3 inhibitors, which are able to reduce PrPSc accumulation in prion-infected cell lines, thereby representing a new therapeutic treatment against prion and prion-like diseases.
The development of specific inhibitors of SERPINA3 with an activity in the nano-molar range is expected. The characterization of structural models of the binding of the small molecules with the protein should allow the identification of novel inhibitors with improved potency.
The research center is looking for licence agreements or joint ventures with industry (pharma companies) or financial agreements with investors interested in developing new drugs.
Technology Keywords
Neurology, Brain Research
Keyword Codes:
06001014
Current Stage of Development
Intellectual Property Rights
Patent(s) applied for but not yet granted
IPR Comments:
The patent owners are: Italian Research Center 1 (50%), German Research Center (37.5%) and Italian Research Center 2 (12.5%). The European search report has shown a complete novelty and inventive step. Supplementary material and supporting data available upon request.
Exploitation of RTD Results
Organisation/Company Type
Organisation/Company Size
Organisation Comments
Detailed Market Application Codes (VEIC)
MA Keyword
Drug delivery and other equipment
MA Keyword Codes:
05003005
Application Domain Description:
Collaboration Type
Comments:
Pharma companies/Investors interested in acquiring and co-developing the technology in the frame of financial, joint venture and license agreement.